CD74-AKT轴是三阴性乳腺癌的潜在治疗目标
Jingchao Wang1, Daoyuan Huang1, Thu Anh Thai Nguyen2
1Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Biology
|July 26, 2024
概括
三重阴性乳腺癌细胞抵抗了细胞灭亡. 向CD74和AKT通路可以恢复这一过程,为TNBC治疗提供了一种新的策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 三阴性乳腺癌 (TNBC) 显示出对亡的抵抗力,这是癌细胞死亡的关键机制.
- 在癌症进展和化学抵抗中,CD74是一种II型跨膜蛋白的作用尚未完全理解.
- 了解TNBC亡耐药性背后的分子机制对于开发有效疗法至关重要.
研究的目的:
- 调查CD74在TNBC中的作用.
- 阐明CD74影响TNBC中亡抵抗的分子机制.
- 探索针对TNBC治疗的CD74通路的治疗策略.
主要方法:
- 癌症患者和患者衍生异种移植 (PDX) 模型中的基因表达分析.
- 评估CD74表达与癌症干细胞 (CSC) 和上皮-介质细胞过渡 (EMT) 属性的相关性.
- 研究CD74,AKT信号传递和FAS介导的亡之间的相互作用.
- 评估AKT抑制剂和CD74衍生在恢复亡中的作用.
主要成果:
- CD74在TNBC中高度表达,与CSC和EMT表型相关.
- AKT的激活对CD74的表达和稳定性至关重要,促进瘤功能.
- CD74与FAS相互作用,抑制FAS介导的亡.
- 准CD74/FAS和CD74-AKT轴协同恢复TNBC细胞中的亡.
结论:
- CD74在促进TNBC进展和亡耐药性方面发挥着重要作用.
- CD74/AKT轴对于维持TNBC中CD74的表达和功能至关重要.
- CD74通过直接与FAS结合来干扰FAS介导的亡.
- 针对CD74/FAS和CD74-AKT通路是TNBC的一个有前途的治疗策略.
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:38Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
01:22PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K